SCHEDULE 13G/A 0002088344-25-000003 0002088344 XXXXXXXX LIVE 1 Common Stock, $0.0001 par value per share 12/31/2025 0001817229 VOR BIOPHARMA INC. 929033207 500 Boylston Street Suite 1350 Boston MA 02116 Rule 13d-1(c) Verve Capital Limited Y0 4297464.00 0.00 4297464.00 0.00 4297464.00 9.9 CO VOR BIOPHARMA INC. 500 Boylston Street, Suite 1350, Boston, MA, 02116. Verve Capital Limited Flat B, 23/F, Panorama Gardens, 103 Robinson Road, Mid-Levels, Hong Kong Samoa Y Row 9 of the Reporting Person's cover page to this Schedule 13G/A sets forth the aggregate number of shares of common stock of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference. The Reporting Person directly holds pre-funded warrants (the "Pre-Funded Warrants") exercisable for up to 5,000,000 shares of common stock. The Pre-Funded Warrants contain a provision (the "Beneficial Ownership Blocker"), which precludes the exercise of the Pre-Funded Warrants to the extent that, following exercise, the Reporting Person, together with its affiliates and other attribution parties, would own more than 9.99% of the outstanding shares of common stock. The Reporting Person is currently prohibited from exercising the Pre-Funded Warrants to the extent that such exercise would result in beneficial ownership of more than 4,297,464 shares of common stock. Due to the Beneficial Ownership Blocker listed in the Pre-Funded Warrants, the Reporting Person's beneficial ownership percentage is 9.99%. Such percentage is based upon the sum of (i) 38,720,196 shares of common stock outstanding as of December 18, 2025, as provided to the Reporting Person by the Issuer and (ii) 4,297,464 shares of common stock issuable upon the exercise of the Pre-Funded Warrants. Due to field limitations of the EDGAR filing system, the percentage listed in Row 11 of the Reporting Person's cover page have been rounded down to 9.9%. Row 5 of the Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by the Reporting Person as of December 31, 2025 and is incorporated by reference. Row 6 of the Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by the Reporting Person as of December 31, 2025 and is incorporated by reference. Row 7 of the Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by the Reporting Person as of December 31, 2025 and is incorporated by reference. Row 8 of the Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by the Reporting Person as of December 31, 2025 and is incorporated by reference. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Verve Capital Limited /s/ Hongtu Zhu 02/17/2026